Digoxin (NSC 95100)

Catalog No.S4290 Synonyms: NSC 95100

For research use only.

Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.

Digoxin (NSC 95100) Chemical Structure

CAS No. 20830-75-5

Selleck's Digoxin (NSC 95100) has been cited by 6 Publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Other ATPase Products

Biological Activity

Description Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.
Targets
Na,K-ATPase α2β3 [1] Na,K-ATPase α2β1 [1] Na,K-ATPase α1β1 [1]
42.8 nM(Ki) 58.7 nM(Ki) 268 nM(Ki)
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
rat hepatocytes M37SfWZ2dmO2aX;uJIF{e2G7 MX\EdpVoKHWydHHr[UBqdiC{YYSgbIVx[XSxY4n0[ZMtKEuvPUCuNVgh|ryP NFfGTJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmyOlYyQSd-MkC5NlY3OTl:L3G+
human hepatocytes MUTGeY5kfGmxbjDhd5NigQ>? M1GzcFAvODVidH:gNVAhfU1? M2m1O2RzfWdidYD0ZYtmKGmwIIPhcoR4cWOqLXP1cJR2emWmIHj1cYFvKGincHH0c4N6fGW|IHH0JFAvODVidH:gNVAhfU1iYYSgN|ch\GWpQzDifUBOcWOqYXXsbZMuVWWwdHXuJItqdmW2aXPzM5NkcW62aXzsZZRqd25ic4DlZ5Rzd3Olb4D5MEBMdT1{LkO5JO69VQ>? MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Mk[2NVkoRjJyOUK2OlE6RC:jPh?=
LLC-PK1 MYnGeY5kfGmxbjDhd5NigQ>? NIS0bnVVWF:WUlHOV3BQWlSHUkqgbY5pcWKrdHnvckBw\iCHMkG3ZoV1[UdidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU2l;MD6wN|fPxE1? NXLpUGRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0NFg2PTdpPkGxOFA5PTV5PD;hQi=>
High Five (BTI-TN5B1-4) NYPO[5N{TnWwY4Tpc44h[XO|YYm= NG\pXZpVWF:WUlHOV3BQWlSHUkqgRXRRKGi7ZILvcJl{cXNiaX6gcYVu[nKjbnWg[pJi[3Srb36g[pJwdSCKaXfoJGZqfmViKFLUTU1VVjWEMT20LUBk\WyuczygT40:OjVwOd88US=> M4PMcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{i1Olg1Lz5zMUe4OVY5PDxxYU6=
LLC-PK1 NIPHXYFHfW6ldHnvckBie3OjeR?= NIjK[oFVWF:WUlHOV3BQWlSHUkqgbY5pcWKrdHnvckBw\iCWYYXyc4Npd2yjdHWgeZB1[WunIHnuJG9ifHB{LXX4dJJme3OrbnegUGxENVCNMTDj[YxteyxiS3m9NE42QM7:TR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTd7Mk[5OEc,OTF5OUK2PVQ9N2F-
LLC-PK1 MYnGeY5kfGmxbjDhd5NigQ>? MUXUVH9VWkGQU2DPVnRGWjpidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU21;MT6wO:69VQ>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTd7Mk[5OEc,OTF5OUK2PVQ9N2F-
LLC-PK1 MoW1SpVv[3Srb36gZZN{[Xl? MU\UVH9VWkGQU2DPVnRGWjpidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU21;MD6yO|nPxE1? MoTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6OEO2OFEoRjFzOEizOlQyRC:jPh?=
MDCK MVTGeY5kfGmxbjDhd5NigQ>? M{HwRXRRZ1SUQV7TVG9TXEWUOjDj[YxtKGGlY4XteYxifGmxbjDpckBQSVSSNFOxMYV5eHKnc4PpcochVUSFSzDj[YxteyxiS329O{45|ryP M2X3OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2OUmzOlA1Lz5zNEm5N|YxPDxxYU6=
MDCK NVjCUVRDTnWwY4Tpc44h[XO|YYm= Mlr0WHBgXFKDTmPQU3JVTVJ8IHPlcIwh[WOldX31cIF1cW:wIHnuJG9CXFB2Q{Gt[ZhxemW|c3nu[{BOTEONIHPlcIx{NCCNbU24{txO NETwOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEm5N|YxPCd-MUS5PVM3ODR:L3G+
TK10 MYXDfZRwfG:6aXPpeJkh[XO|YYm= MWm0PEBpenN? NX7Q[pNiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXEtzMDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODF2Nt88US=> NYT2[3poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNFk{OTVpPkG2N|A6OzF3PD;hQi=>
MCF7 M{Tn[WN6fG:2b4jpZ4l1gSCjc4PhfS=> NHvM[W81QCCqcoO= MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6wNlQy|ryP MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ|MEmzNVUoRjF4M{C5N|E2RC:jPh?=
K562 NFrEdFJEgXSxdH;4bYNqfHliYYPzZZk> NYL6c4QzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCkeTDYWHQh[XO|YYmsJGlEPTB;MD6wNlgz|ryP M1;iXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4M{C5N|E2Lz5zNkOwPVMyPTxxYU6=
UACC62 Ml70R5l1d3SxeHnjbZR6KGG|c3H5 M1uyV|Q5KGi{cx?= Mk\yR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWWFESzZ{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4xOjl3zszN NGr0NJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
HeLa MY\DfZRwfG:6aXPpeJkh[XO|YYm= MlnZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGRPSSC{ZYDsbYNifGmxbjDifUBqdWGpaX7nJIFv[Wy7c3nz M2LrUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6ME[2NFU2Lz5zOEC2OlA2PTxxYU6=
HeLa NGLPenpHfW6ldHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKG2rdH;zbZMhcW5iaIXtZY4hUGWOYTDj[YxteyCkeTDpcYFocW6pIHHuZYx6e2m| NUnEVXpDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwOlYxPTVpPkG4NFY3ODV3PD;hQi=>
colon cancer MX3DfZRwfG:6aXPpeJkh[XO|YYm= MVS3NkBpenN? MnvuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDGUWNCKG2ndHjv[EwhUUN3ME2wMlHPxE1? NVnXNHhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PVQ4OzNpPkG5PFk1PzN|PD;hQi=>
CC20 M1vrN2N6fG:2b4jpZ4l1gSCjc4PhfS=> MnjkO|IhcHK| MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR|IxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDGUWNCKG2ndHjv[EwhUUN3ME2wMlI1|ryP Mm\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUS3N|MoRjF7OEm0O|M{RC:jPh?=
HCT116 MX3DfZRwfG:6aXPpeJkh[XO|YYm= NInu[mU4OiCqcoO= MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVAvOjgQvF2= M{TNdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
HT-29 NF3TVI1EgXSxdH;4bYNqfHliYYPzZZk> MVi3NkBpenN? Mlu0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVEvPM7:TR?= NHjhWo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi5OFc{Oyd-MUm4PVQ4OzN:L3G+
Hs578Bst NF;TVoxEgXSxdH;4bYNqfHliYYPzZZk> NFixdXQ4OiCqcoO= NVS0[mtJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHN3N{jCd5Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTB;MD6wOO69VQ>? MlvJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
Hs578T M1fTTWN6fG:2b4jpZ4l1gSCjc4PhfS=> NHLMTmE4OiCqcoO= NXXJSGpMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHN3N{jUJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTBwMkWx{txO MnHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
T47D MonhR5l1d3SxeHnjbZR6KGG|c3H5 NWXKWYtmPzJiaILz NULoTlJMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NF0xNjZ4zszN M1zNcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G2NVY5Lz5{MkOxOlE3QDxxYU6=
SK-BR-3 NUHoW|hqS3m2b4TvfIlkcXS7IHHzd4F6 NHjTO5U4OiCqcoO= NUDLcWdJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvQmKtN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1zLkC4{txO NYP3PI9JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
MCF7 NHLpU|dEgXSxdH;4bYNqfHliYYPzZZk> NXPNb45oPzJiaILz MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyPUSuO:69VQ>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
Hs578Bst NEToXmtEgXSxdH;4bYNqfHliYYPzZZk> M{S5NVQxKHWP MXK3NkBpenN? MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDId|U4QEK|dDDj[YxteyCjdDC0NEB2VSCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbDygTWM2OD12Nz63{txO Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
CHO M4P5bWZ2dmO2aX;uJIF{e2G7 NWLFW4JxeEmFNUCgeoFtfWW|IH\vdkB{d2SrdX2g[ox2d3Knc3PlbY4hMDFyIIXNLUB2eHSja3WgbY4hV0GWUEHCNU11emGwc3\lZ5Rm\CCFSF:gZ4VtdHNuIFnDOVA:Oy5{M{W5OO69VQ>? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MUSxOUc,OjN3N{G0NVU9N2F-
CHO MWHGeY5kfGmxbjDhd5NigQ>? NFrR[3FxUUN3MDD2ZYx2\XNiZn;yJJNw\Gm3bTDmcJVwemW|Y3XpckApOTBidV2pJJVxfGGtZTDpckBQSVSSMVKzMZRz[W6|ZnXjeIVlKEOKTzDj[YxteyxiSVO1NF0yOy5zOEK2{txO MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MUSxOUc,OjN3N{G0NVU9N2F-
Hs683 MknsR5l1d3SxeHnjbZR6KGG|c3H5 M2rDUVMh\GG7cx?= NHv5PZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJezZ6MzDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODUQvF2= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNkCwOUc,OjN5ME[wNFU9N2F-
A549 MX3DfZRwfG:6aXPpeJkh[XO|YYm= NFfjT44{KGSjeYO= MnzER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFXPxE1? MlrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
PC3 MmfxR5l1d3SxeHnjbZR6KGG|c3H5 M2fteFMh\GG7cx?= M3;oXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFc2|ryP NVvuTpI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFYxODVpPkKzO|A3ODB3PD;hQi=>
U373 M{PYOmN6fG:2b4jpZ4l1gSCjc4PhfS=> M330[FMh\GG7cx?= MnKzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVM4OyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVQ3|ryP Ml[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
SK-MEL-28 NI\OOZBEgXSxdH;4bYNqfHliYYPzZZk> NYrhdJNiOyCmYYnz NGm2[JNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytNlgh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD1yLkK2Ou69VQ>? NYLNemh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFYxODVpPkKzO|A3ODB3PD;hQi=>
MCF7 M{nSNWN6fG:2b4jpZ4l1gSCjc4PhfS=> NHTHS|Q{KGSjeYO= MnTMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOFI3|ryP NEXCSGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlAxPSd-MkO3NFYxODV:L3G+
Drosophila Schneider cells M{ToOGZ2dmO2aX;uJIF{e2G7 NH7Y[G5CdnSjZ3;ubZN1KGGldHn2bZR6KGG2IITyZY5{[WO2aY\heIlwdiCmb33hbY4hd2ZiUl;S[4FudWG2IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhW2OqbnXp[IVzKGOnbHzzJINwNWW6cILld5NqdmdiR3HsOE1FVkFiYnnu[Ilv\yCmb33hbY4tKEmFNUC9Nu69VQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2MES4Okc,OjRyNEC0PFY9N2F-
Drosophila Schneider cells NXjqVHB7TnWwY4Tpc44h[XO|YYm= MX\BcpRi\2:waYP0JIFkfGm4aYT5JIF1KHS{YX7zZYN1cX[jdHnvckBld22jaX6gc4YhWk:UZ3HtcYF1KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFTyc5NweGirbHGgV4NpdmWrZHXyJINmdGy|IHPvMYV5eHKnc4PpcochT2GuND3EUmEh[mmwZHnu[{Bld22jaX6sJGlEPTB;Mt88US=> M2DZNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESwOFg3Lz5{NEC0NFQ5PjxxYU6=
RKO-AS45-1 MWHDfZRwfG:6aXPpeJkh[XO|YYm= MVq0PEBpenN? Mkn0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVmtQNUGVNEWtNUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwNENOwG0> NWDjRnVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa NHfLe5pEgXSxdH;4bYNqfHliYYPzZZk> MoPtOFghcHK| MmD1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKuNu69VQ>? NWj1N4xCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa NFi5cIJHfW6ldHnvckBie3OjeR?= NG\1b3IyPTBibl2= NGm1RlAzPCCqcoO= NITsNWRKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? NXfS[VJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa M3LMTmZ2dmO2aX;uJIF{e2G7 NXrMZ3ZyOTVyIH7N NYm2eWpwOjRiaILz NX34XmdDUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? M4myRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa MWTGeY5kfGmxbjDhd5NigQ>? NV\5clhZOTVyIH7N NULudXgyOjRiaILz NWD5[FU3UW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? MkDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa MXfGeY5kfGmxbjDhd5NigQ>? NIXo[HQyPTBibl2= NYe0TXNKOjRiaILz NHfsVlJKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa NYKzcY5QTnWwY4Tpc44h[XO|YYm= Ml\oNVUxKG6P MYGyOEBpenN? NV31O5dFUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NYnnWoNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa NVXoS4tJTnWwY4Tpc44h[XO|YYm= MnPONVUxKG6P MoTQNlQhcHK| M3;5UmlvcGmkaYTpc44hd2ZiTnGoL{kwUyhtKTDBWHBie2ViaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5o MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa NVq3dXlGTnWwY4Tpc44h[XO|YYm= M3yzSFE2OCCwTR?= NYj3[4dtOjRiaILz M13od2lvcGmkaYTpc44hd2ZiTnGoL{kwUyhtKTDBWHBie2ViaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5o M3zjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa MkjDSpVv[3Srb36gZZN{[Xl? Mmr1NVUxKG6P NUfLSVd7OjRiaILz NHPCbIlKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
Kasumi-1 NWDnVFlMS3m2b4TvfIlkcXS7IHHzd4F6 NYrnepZJPDhiaILz MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLZZN2dWlvMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNiYYPzZZktKEmFNUC9NE4xQTQQvF2= NYfZdlN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
MV4-11 NIHOb2tEgXSxdH;4bYNqfHliYYPzZZk> NFmyRo01QCCqcoO= MmjQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlEyOc7:TR?= NH3Q[Io9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m4N|g1Oid-Mke5PFM5PDJ:L3G+
HT-29 M2nVe2N6fG:2b4jpZ4l1gSCjc4PhfS=> M2\4SVczKGi{cx?= MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6zPO69VQ>? NVKwRm1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
H1299 NU\XOngzS3m2b4TvfIlkcXS7IHHzd4F6 MYeyOEBpenN? NUfxdGtkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDF{OUmgZ4VtdHNiaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPDcQvF2= M2ryfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUizPFQzLz5{N{m4N|g1OjxxYU6=
CCD-112CoN MVjDfZRwfG:6aXPpeJkh[XO|YYm= M2TsXFczKGi{cx?= MoC2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NFNTFzMlPvUkBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3ME2yMlTPxE1? NEiyZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m4N|g1Oid-Mke5PFM5PDJ:L3G+
DU145 M4fQeWZ2dmO2aX;uJIF{e2G7 MVy1NEB2VQ>? NHTtVpY2KGi{cx?= NUHOUHJ{UW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 M2PlOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 M3O2Z2Z2dmO2aX;uJIF{e2G7 MkfBOVAhfU1? MlLmOUBpenN? NWDU[XVZUW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 Ml7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 NFTyTXJHfW6ldHnvckBie3OjeR?= M3vB[lUxKHWP NYHRRohFPSCqcoO= NVzjN|dtUW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 M2[1U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 NU\EW4VkTnWwY4Tpc44h[XO|YYm= NVjUe4dwPTBidV2= MXu1JIhzew>? M3PHSmlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 MXHGeY5kfGmxbjDhd5NigQ>? MYO1NEB2VQ>? NH;TeY42KGi{cx?= M2\IcGlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 M1rTUGZ2dmO2aX;uJIF{e2G7 NEGzTHI2OCC3TR?= NHLmdlU2KGi{cx?= MXrJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? M2\kelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 NGDwN|lHfW6ldHnvckBie3OjeR?= M2TBeFUxKHWP MkizOUBpenN? M1S2fmlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 MlTXSpVv[3Srb36gZZN{[Xl? MXO1NEB2VQ>? MWK1JIhzew>? NXW5TYt4UW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 NH7Ee449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGyNFI2OSd-M{GxNlAzPTF:L3G+
Assay
Methods Test Index PMID
Western blot p-Src / Src / p-EGFR / EGFR / p-STAT3 / STAT3 ; p-PI3K / PI3K / p-AKT / AKT / p-MEK / MEK / p-ERK / ERK / p-FAK / FAK / p-SAPK/JNK / p-Paxillin / Paxillin / p-p130Cas / p130Cas ; Nrf2 25955608 30735911
Growth inhibition assay Cell viability 25955608

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.

2mg/mL

Chemical Information

Molecular Weight 780.94
Formula

C41H64O14

CAS No. 20830-75-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05137626 Completed Drug: AT-527 + digoxin Healthy Volunteers Study Atea Pharmaceuticals Inc.|Hoffmann-La Roche November 3 2021 Phase 1
NCT05014087 Recruiting Drug: Intravenous digoxin Acute Alcoholic Hepatitis|Chemical and Drug Induced Liver Injury|Alcohol-Induced Disorders|Steatohepatitis Caused by Ingestible Alcohol Yale University October 8 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Digoxin (NSC 95100) | Digoxin (NSC 95100) supplier | purchase Digoxin (NSC 95100) | Digoxin (NSC 95100) cost | Digoxin (NSC 95100) manufacturer | order Digoxin (NSC 95100) | Digoxin (NSC 95100) distributor